insights_auto
Obeti: Optimistični obeti: 15.8 %·Pesimistični obeti: 21.1 %
Odpri analizochevron_right
GSK:NYSE
GSK plc
49,70 $
arrow_upward
+0,93%(+0,46) 1D
50,21 $
arrow_upward
+1,03% (+0,51)todayPred odprtjem
Zaprto: 28. sep., 16:00:03 GMT -4 · USD
search
Vsi simboli
1D
5D
1M
6M
TLDD
1L
5L
MAKS
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za GSK …
Odpri
49,17 $
Visoka
49,80 $
Nizka
48,98 $
Tržna kapitalizacija
99,88 mrd.
Povprečni promet
2,95 mio.
Promet
45,01 tis.
Dividenda
3,66 %
Četrtletna dividenda
0,45 $
Prvi trgovalni dan brez upravičenja do dividende
13. avg. 2026
Razmerje med ceno delnice in čistim dobičkom
15,89
52-tedenski najvišji tečaj
61,70 $
52-tedenski najnižji tečaj
40,36 $
Čisti dobiček na delnico
3,13 $
Beta
0,27
Št. izdanih delnic
2,02 mrd.
Št. zaposlenih
67 tis.
Odpri
49,17 $
Visoka
49,80 $
Nizka
48,98 $
Tržna kapitalizacija
99,88 mrd.
Povprečni promet
2,95 mio.
Promet
45,01 tis.
Dividenda
3,66 %
Četrtletna dividenda
0,45 $
Prvi trgovalni dan brez upravičenja do dividende
13. avg. 2026
Razmerje med ceno delnice in čistim dobičkom
15,89
52-tedenski najvišji tečaj
61,70 $
52-tedenski najnižji tečaj
40,36 $
Čisti dobiček na delnico
3,13 $
Beta
0,27
Št. izdanih delnic
2,02 mrd.
Št. zaposlenih
67 tis.
Novice
Iz spletnih virov in novičarskih partnerjev
AD HOC NEWS
·
pred 11 urami
GSK stock last trades at GBp 1,860.00 on September 28, 2026
Zacks
·
pred 16 urami
Merck, Daiichi Withdraw FDA Filing for Lung Cancer Therapy
Traders Union
·
pred 1 dnevom
Nuvalent acquisition supports GSK stock as it holds near GBX1,834 support
Profil
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
Vizitka: GSK plc
Generalni direktorEmma Walmsley | Emma Walmsley
Št. zaposlenih66,8 tis.
Ustanovljeno27. dec. 2000
Sedež-
Sektor-
Spletno mestogsk.com